Core Viewpoint - GlucoTrack (GCTK.US) experienced a significant increase of over 123%, reaching $10.91, following the announcement of a deal to sell up to $20 million in common stock [1] Company Summary - GlucoTrack specializes in the development of implantable continuous glucose monitoring devices that directly measure blood glucose levels, eliminating lag time, making it suitable for diabetes patients [1] Financial Summary - The agreement with Sixth District Capital involves the sale of up to $20 million in common stock, which may provide additional capital for the company's operations and growth [1]

Core Insights - GlucoTrack (GCTK.US) experienced a significant increase of over 123%, reaching a price of $10.91 [1] - The company announced an agreement with Sixth District Capital to sell up to $20 million in common stock [1] - GlucoTrack specializes in developing implantable continuous glucose monitoring devices that directly measure blood glucose levels, eliminating lag time, and are suitable for diabetes patients [1]